Skip to main content
Matt Thomas Watch List

6/19 Watch List – ROX Back on High Alert After Earnings Call

By June 18, 2017March 23rd, 2023No Comments

Summary of Recent Portfolio Moves:

A few months ago, I started scaling into a position in ROX at $1.50 and it has since become one of my best trades of the year. It reached a high of $2.22 on 6/6 and I was able to capture quite a bit of profits along the way. Since that day, ROX has slipped a bit which forced me to exit my position on 6/9 when it broke below $1.90. I just couldn’t let this trade get away from me, so I decided to lock in profits before it potentially turned into a loser – Check Out My 6/14 Watch List For Details.

This turned out to be a pretty good decision as the stock dropped down to a low of $1.48 on 6/13. I considered adding back my position in this region, but wanted confirmation that the flush was over. Just two days later, shares were back up near $2.00 on strong revenue growth and increased gross margins. I had a feeling the recent deal that put Goslings Stormy Ginger Beer on the shelves of 4,500 Walmart stores would have a significant impact on financials, and it seems like that will be the case moving forward. Overall, it appears that ROX is poised for growth in the months to come. [Link to ROX Earnings Analysis]

My Open Positions as of Friday, 6/16:

Ticker Number of Shares Average Price
ROX 900 $1.84
LQMT 682 $0.27
GRPN 150 $3.15
ZGNX 7 $14.50
ITEK 200 $1.78
CYTX 300 $1.04
TZA 40 $16.44

Here’s a Breakdown of All Open Positions:

ROX (Castle Brands Inc.)

Thesis: I’ve covered much of my thesis in Previous Watch Lists and I still believe ROX has substantial growth-potential. They just signed a deal with Walmart back in March to get their ginger beer on the shelves of 4,500 stores, reported a positive fiscal year net income for the first time in company history, and are seemingly a Strong Takeover Candidate. From a technical standpoint, it looks like support is building in the $1.70-1.80 range, which is the area I’m monitoring for potential adds to my position. I re-entered the trade on 6/15 after the positive earnings release.

Price at Close 6/16: $1.88
Buy Zone: $1.70-1.80
Disclosure: Currently Own 900 Shares at $1.84

ROX Chart

LQMT (Liquidmetal Technologies Inc.)

Thesis: Remains the same as discussed in my 5/15 Watch List and 6/1 Watch List. Share price has been bouncing around in the $0.25-0.30 range for the past couple months and I think it’s only a matter of time before this one spikes. I’d like to add to my position in the $0.25-0.27 range in the coming weeks if the share price dips again. Looks like I missed a decent opportunity to do so this past week around $0.26. Apple iPhone rumors and the CEO’s track record are two of the main catalysts I think can drive this stock higher.

Price at Close 6/16: $0.29
Buy Zone: $0.25-0.27
Disclosure: Currently Own 682 Shares at $0.27

LQMT Chart

GRPN (Groupon Inc.)

Thesis: I was close to stopping out of this one at times throughout the past week, but this has finally established strong support at $3.00 and is starting to rally into the $3.20’s. This stock has been beaten down over the past year and is due for a pop. Maybe the Alibaba buyout rumors will start swirling again – that type of headline can generate quite a bit of buzz. Four straight days of strong price action on the chart is a great sign of a reversal.

Price at Close 6/16: $3.22
Buy Zone: $3.00-3.10
Disclosure: Currently Own 150 Shares at $3.15

GRPN Chart

ZGNX (Zogenix Inc.)

Thesis: This one jumped back on my radar Last Week when I found a couple upcoming catalysts in the BioPharmCatalysts.com database. From a technical standpoint, I like the consolidation of price action and support above the $14.00 level. This is a ticker I’ve played on multiple catalyst run-ups in the past and had pretty good success with it. I’m hoping for a similar run-up as the phase 3 catalysts approach in the third quarter and second half of 2017. I took a small position this past week just to get some exposure and looking for a pullback near $14.00 for a larger add.

Price at Close 6/16: $14.60
Buy Zone: $13.75-14.25
Disclosure: Currently Own 7 Shares at $14.50

ZGNX Chart

ITEK (Inotek Pharmaceuticals Corporation)

Thesis: With strong support above $1.60,  I expect this stock to trend upwards as the mid-2017 Phase 2 Glaucoma catalyst date approaches. I already booked some profits on part of my position in the $1.90’s, but I’m looking for a larger move up on the rest. It’s trading above the 50-day moving average but hasn’t yet been able to crack $2.00. This ticker is part of the SEC 5-Cent Tick Program which seems to be putting a damper on how it’s trading. But if this can somehow work its way into the gap above $2.30, it can potentially run quite a bit.

Price at Close 6/16: $1.88
Buy Zone: $1.60-1.75
Disclosure: Currently Own 200 Shares at $1.78

ITEK Chart

CYTX (Cytori Therapeutics Inc.)

Thesis: There’s strong support in the low $1.90’s from back in May that I certainly wouldn’t want to see the price break below. The past few trading sessions have been tough on this stock, but I’m looking for a potential add in the $0.90’s if the selling action slows. This is a biotech stock with phase 3 data due early 3Q 2017 for Scleroderma.

Price at Close 6/16: $0.98
Buy Zone: $.90-1.00
Disclosure: Currently Own 300 Shares at $1.04

CYTX Chart

TZA (Direxion Daily Small Cap Bear 3X Shares)

Thesis: This is a play that goes against the IWM. In other words, if the small-cap index goes up, TZA goes down, and if the small-cap index goes down, TZA goes up. The IWM has been hitting it’s head on resistance in the low $1.40’s, and with so much political and economic uncertainty recently, this can definitely have a negative impact on the market as a whole, especially small caps. I think a correction back down to lower levels could be in order.

Price at Close 6/16: $16.68
Buy Zone: Watching IWM for confirmation of resistance at $140 level
Disclosure: Currently Own 40 Shares at $16.44

IWM Chart

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. PLEASE REFER TO DISCLAIMER.

Matt Thomas

Founder of TradingParadigm.com, Creator of the Trading Success Framework Course & Trading Paradigm Skool Community, and Intraday Futures Trader Using Auction Market Theory & Profiling (Volume & Market Profile).

Leave a Reply